留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

全身型幼年特发性关节炎的发病机制

马明圣 肖海鹃 宋红梅

马明圣, 肖海鹃, 宋红梅. 全身型幼年特发性关节炎的发病机制[J]. 协和医学杂志, 2016, 7(2): 128-131. doi: 10.3969/j.issn.1674-9081.2016.02.010
引用本文: 马明圣, 肖海鹃, 宋红梅. 全身型幼年特发性关节炎的发病机制[J]. 协和医学杂志, 2016, 7(2): 128-131. doi: 10.3969/j.issn.1674-9081.2016.02.010

全身型幼年特发性关节炎的发病机制

doi: 10.3969/j.issn.1674-9081.2016.02.010
详细信息
    通讯作者:

    宋红梅 电话:010-69156276, E-mail:songhm1021@hotmail.com

  • 中图分类号: R593.2;R596.3

  • [1] Park H, Bourla AB, Kastner DL, et al.Lighting the fires within:the cell biology of autoinflammatory diseases[J]. Nat Rev Immunol, 2012, 12:570-580. doi:  10.1038/nri3261
    [2] Vastert SJ, Kuis W, Grom AA. Systemic JIA:New developments in theunderstanding of the pathophysiology and therapy[J]. Best Pract Res Clin Rheumatol, 2009, 23:655-664. doi:  10.1016/j.berh.2009.08.003
    [3] Yokota S, Kikuchi M, Nozawa T, et al. Pathogenesis of systemic inflammatory diseases in childhood:"Lessons from clinical trials of anti-cytokine monoclonal antibodies for Kawasaki disease, systemic onset juvenile idiopathic arthritis, and cryopyrin-associated periodic fever syndrome"[J].Mod Rheumatol, 2015, 25:1-10. doi:  10.3109/14397595.2014.902747
    [4] Mellins ED, Macaubas C, Grom AA, et al. Pathogenesis of systemic juvenile idiopathic arthritis:some answers, more questions[J].Nat Rev Rheumatol, 2011, 7:416-426. doi:  10.1038/nrrheum.2011.68
    [5] Barker BR, Taxman DJ, Ting JP. Cross-regulation between the IL-1beta/IL-18 processing inflammasome and other inflammatory cytokines[J]. Curr Opin Immunol, 2011, 23:591-597. doi:  10.1016/j.coi.2011.07.005
    [6] Kessel C, Holzinger D, Foell D. Phagocyte-derived S100 proteins in autoinflammation:putative role in pathogenesis and usefulness as biomarkers[J]. Clin Immunol, 2013, 147:229-241. doi:  10.1016/j.clim.2012.11.008
    [7] Mellins ED, Macaubas C, Grom AA. Pathogenesis of systemic juvenile idiopathic arthritis:some answers, more questions[J]. Nat Rev Rheumatol, 2011, 7:416-426. doi:  10.1038/nrrheum.2011.68
    [8] Llamas-Covarrubias MA, Valle Y, Bucala R, et al.Macrophage migration inhibitory factor (MIF):genetic evidence for participation in early onset and early stage rheumatoid arthritis[J].Cytokine, 2013, 61:759-765. doi:  10.1016/j.cyto.2012.12.032
    [9] Wakil SM, Monies DM, Abouelhoda M, et al. Association of a mutation in LACC1 with a monogenic form of systemic juvenile idiopathic arthritis[J]. Arthritis Rheumatol, 2015, 67:288-295. doi:  10.1002/art.38877
    [10] de Jesus AA, Goldbach-Mansky R. Newly recognized Mendelian disorders with rheumatic manifestations[J]. Curr Opin Rheumatol, 2015, 27:511-519. doi:  10.1097/BOR.0000000000000207
    [11] Balow JE Jr, Ryan JG, Chae JJ, et al. Microarray-based gene expressionprofiling in patients with cryopyrin-associated periodic syndromes defines adisease-related signature and IL-1-responsive transcripts[J]. Ann Rheum Dis, 2013, 72:1064-1070. doi:  10.1136/annrheumdis-2012-202082
    [12] Ayaz NA, Ozen S, Bilginer Y, et al. MEFV mutations in systemic onset juvenile idiopathic arthritis[J]. Rheumatology (Oxford), 2009, 48:23-25. http://www.ncbi.nlm.nih.gov/pubmed/18984609
    [13] Hinks A, Martin P, Thompson SD, et al. Autoinflammatory gene polymorphisms and susceptibility to UK juvenile idiopathic arthritis[J].Pediatr Rheumatol Online J, 2013, 11:14. doi:  10.1186/1546-0096-11-14
    [14] Sikora KA, Grom AA. Update on the pathogenesis and treatment of systemic idiopathic arthritis[J]. Curr Opin Pediatr, 2011, 23:640-646. doi:  10.1097/MOP.0b013e32834cba24
    [15] Gaspari S, Marcovecchio ML, Breda L, et al. Growth in juvenile idiopathic arthritis:the role of inflammation[J].Clin Exp Rheumatol, 2011, 29:104-110. http://europepmc.org/abstract/MED/21269577
    [16] Yokota S, Imagawa T, Mori M, et al. Longterm safety and effectiveness of the anti-interleukin 6 receptor monoclonal antibody tocilizumab in patients with systemic juvenile idiopathic arthritis in Japan[J].J Rheumatol, 2014, 41:759-767. doi:  10.3899/jrheum.130690
    [17] Kostik MM, Dubko MF, Masalova VV, et al. Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis[J].Pediatr Rheumatol Online J, 2015, 23:13-17. doi:  10.1186/1546-0096-13-4
    [18] Izumi K, Kaneko Y, Yasuoka H, et al. Tocilizumab is clinically, functionally, and radiographically effective and safe either with or without low-dose methotrexate in active rheumatoid arthritis patients with inadequate responses to DMARDs and/or TNF inhibitors:a single-center retrospective cohort study (KEIO-TCZ study) at week 52[J]. Mod Rheumatol, 2015, 25:31-37. doi:  10.3109/14397595.2014.897793
    [19] De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis[J]. N Engl J Med, 2012, 367:2385-2395. doi:  10.1056/NEJMoa1112802
    [20] Ilowite NT, Prather K, Lokhnygina Y, et al.Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis[J].Arthritis Rheumatol, 2014, 66:2570-2579. doi:  10.1002/art.38699
    [21] Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France:a nationwide survey[J].Orphanet J Rare Dis, 2015, 15:10-19. http://pubmedcentralcanada.ca/pmcc/articles/PMC4340831/
    [22] Frosch M, Ahlmann M, Vogl T, et al. Themyeloid-related proteins 8 and 14 complex, a novel ligand of toll-like receptor4, and interleukin-1beta form a positive feedback mechanism in systemic-onsetjuvenile idiopathic arthritis[J]. Arthritis Rheum, 2009, 60:883-891. doi:  10.1002/art.24349
    [23] Wilson DC1, Marinov AD, Blair HC, et al. Follistatin-like protein 1 is a mesenchyme-derived inflammatory protein and may represent a biomarker for systemic-onset juvenile rheumatoid arthritis[J]. Arthritis Rheum, 2010, 62:2510-2516. doi:  10.1002/art.27485
    [24] deJager W, Hoppenreijs EP, Wulffraat NM, et al. Blood and synovial fluid cytokine signatures in patients withjuvenile idiopathic arthritis:a cross-sectional study[J]. Ann Rheum Dis, 2007, 66:589-598. doi:  10.1136/ard.2006.061853
    [25] Shimizu M, Nakagishi Y, Yachie A. Distinct subsets of patients with systemicjuvenile idiopathic arthritis based on their cytokine profiles[J]. Cytokine, 2013, 61:345-348. doi:  10.1016/j.cyto.2012.11.025
    [26] Ravelli A, Minoia F, Davì S, et al.Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis[S/OL].Arthritis Rheumatol, 2015, 8.http://www.researchgate.net/publication/281325601. doi: 10.1002/art.39332.
    [27] Reddy VV, Myles A, Cheekatla SS, et al. Soluble CD25 in serum:a potential marker for subclinical macrophage activation syndrome in patients with active systemic onset juvenile idiopathic arthritis[J].Int J Rheum Dis, 2014, 17:261-267. doi:  10.1111/1756-185X.12196
    [28] Ibarra MF, Klein-Gitelman M, Morgan E, et al. Serum neopterin levels as a diagnostic marker of hemophagocyticlymphohistiocytosis syndrome[J]. Clin Vaccine Immunol, 2011, 18:609-614. doi:  10.1128/CVI.00306-10
    [29] Hazen MM, Woodward AL, Hofmann I, et al. Mutations of thehemophagocytic lymphohistiocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis[J]. Arthritis Rheum, 2008, 58:56-570.
    [30] Zhang K, Biroschak J, Glass DN, et al. Macrophage activation syndromein patients with systemic juvenile idiopathic arthritis is associated with MUNC13-4 polymorphisms[J]. Arthritis Rheum, 2008, 58:2892-2896. doi:  10.1002/art.23734
    [31] Yanagimachi M, Goto H, Miyamae T, et al. Association of IRF5 polymorphisms with susceptibility to hemophagocytic lymphohistiocytosis in children[J].J Clin Immunol, 2011, 31:946-951. doi:  10.1007/s10875-011-9583-x
    [32] Yanagimachi M, Naruto T, Miyamae T, et al. Association of IRF5 polymorphisms with susceptibility to macrophage activation syndrome in patients with juvenile idiopathic arthritis[J].J Rheumatol, 2011, 38:769-774. doi:  10.3899/jrheum.100655
  • 加载中
计量
  • 文章访问数:  40
  • HTML全文浏览量:  4
  • PDF下载量:  52
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-08-15
  • 刊出日期:  2016-03-30

目录

    /

    返回文章
    返回